Trials & Filings

FDA Approves J&J’s Hep C Pill

Olysio shown to cure patients in less time

The FDA has approved Johnson & Johnson’s Olysio ( assimeprevir) as a treatment for chronic hepatitis C virus infection. Olysio is a protease inhibitor that blocks a specific protein needed by the virus to replicate, and is used in combination with interferon, given by injection, and ribavirin. Olysio was shown in clinical trials to cure patients with a shorter duration of treatment.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters